1. Hillard PJ, Berek JS, Barss VA et al. Guidelines for women’s health care: A resource manual. 3rd ed. Washington, DC: American College of Obstetricians and Gynecologists, 2007.
2. Allen RH, Cwiak CA. Contraception for midlife women. Menopause 2016; 23 (1).
3. Менопаузальная гормонотерапия и сохранение здоровья женщин в зрелом возрасте. Клинические рекомендации (протокол лечения). Проблемы репродукции. 2016; 6: 425–47. / Menopauzal'naja gormonoterapija i sohranenie zdorov'ja zhenshhin v zrelom vozraste. Klinicheskie rekomendacii (protokol lechenija). Problemy reprodukcii. 2016; 6: 425–47. [in Russian]
4. Schlaff WD, Lynch AM, Hughes HD et al. Manipulation of the pill-free interval in oral contraceptive pill users: the effects on follicular suppression. Am J Obstet Gynecol 2004; 190: 943–51.
5. Sulak PJ, Scow RD, Preece C et al. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol 2000; 95: 261–6.
6. Coffee A, Kuehl TK, Willis SA, Sulak PJ. Oral contraceptives and premenstrual symptoms: comparison of a 21/7 and extended regimen. Am J Obstet Gynecol 2006; 195: 1311–9.
7. Vandever MA, Kuehl TJ, Sulak PJ et al. Evaluation of pituitary–ovarian axis suppression with three oral contraceptive regimens. Contraception 2008; 77 (3): 162–70.
8. Yonkers KA, Brown C, Pearlstein TB et al. Efficacy of a new low dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol 2005; 106: 492–501.
9. Davis AR, Kroll R, Soltes B et al. Return to menses after continuous use of a low-dose oral contraceptive. Obstet Gynecol 2006; 107: 3S.
10. Archer DF, Jensen JT, Johnson JV et al. Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results. Contraception 2006; 74 (6): 439–45.
11. Burness C.B. Extended-cycle Levonorgestrel/ethinylestradiol and low-dose ethinylestradiol (Seasonique): a review of its use as an oral contraceptive. Drugs 2015; 75 (9): 1019–26. DOI: 10.1007/s40265-015-0407-9
12. Den Tonkelaar I, Oddens BJ. Preferred frequency and characteristics of menstrual bleeding in relation to reproductive status, oral contraceptive use, and hormone replacement therapy use. Contraception 1999; 59: 357–62.
13. Andrist LC, Arias RD, Nucatola D et al. Women’s and providers’ attitudes toward menstrual suppression with extended use of oral contraceptives. Contraception 2004; 70: 359–63.
14. Glasier AF, Smith KB, van der Spuy ZM et al. Amenorrhea associated with contraception—an international study on acceptability. Contraception 2003; 67: 1–8.
15. Miller L, Hughes JP. Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: a randomized trial. Obstet Gynecol 2003; 101: 653–61.
16. Аrcher DF, Kovalevsky G, Ballagh S, Grubb GS. Effect on ovarian activity of a continuous-use regimen of oral levonorgestrel/ethinyl estradiol. Fertil Steril 2005; 84 (Suppl.): S24.
17. Gold R. Rekindling efforts to prevent unplanned pregnancy: A matter of “equity and common sense”. Guttmacher Policy Rev 2006; 9: 2–6.
18. Davis SR, Bitzer J, Giraldi A et al. Change to either a nonandrogenic or androgenic progestin-containing oral contraceptive preparation s associated with improved sexual function in women with oral contraceptive-associated sexual dysfunction. J Sex Med 2013; 10 (12): 3069–79.
19. Nappi RE, Davis SR, Parke S et al. Effects of Estradiol Valerate/Dienogest Compared with Ethinyl Estradiol/Levonorgestrel on Libido. Endocr Rev 2011; 32: 1–315.
20. Карахалис Л.Ю., Федорович О.К. Дифференцированное применение комбинированных пероральных контрацептивов. Акушерство и гинекология. 2006; 6: 51–4. / Karakhalis L.Iu., Fedorovich O.K. Differentsirovannoe primenenie kombinirovannykh peroral'nykh kontratseptivov. Akusherstvo i ginekologiia. 2006; 6: 51–4. [in Russian]
21. Карахалис Л.Ю. Пролонгированный режим: контрацептивные и неконтрацептивные преимущества. Consilium Medicum. 2017; 19 (6): 54–6. DOI: 10.26442/2075-1753_19.6.54-56 / Karakhalis L.Yu. The prolonged regime: contraceptive and non-contraceptive benefits. Consilium Medicum. 2017; 19 (6): 54–56. DOI: 10.26442/2075-1753_19.6.54-56 [in Russian]
22. Michels KA et al. Oral Contraceptive Use and Risks of Cancer in the NIH-AARP Diet and Health Study. Am J Epidemiol 2018. DOI: 10.1093/aje/kwx388
23. Shrader SP, Dickerson LM. Extended- and Continuous-Cycle Oral Contraceptives. Pharmacotherapy 2008; 28 (8): 1033–40.
24. Lidegaard O. Hormonal cointraception and venous thromboembolic risk in midlife women. Maturitas 2013; 74 (1): 1–2. DOI: 10.1016/j.maturitas.2012.09.015
25. Vinogradova Y, Coupland C, Hippisley-Cox J. Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ 2015; 350: h2135. DOI: 10.1136/bmj.h2135
26. ACOG Committee on Practice Bulletins-Gynecology. ACOG practice bulletin. No. 73: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol 2006; 107 (6): 1453–72. 
27. Department of Reproductive Health, World Health Organization. Medical Eligibility Criteria for Contraceptive Use. 4th ed. 2009. http://www.who. int/reproductivehealth/publications/family_planning/9789241563888/en/index.html 
28. Kaunitz A. Hormonal Contraception in Women of Older Reproductive Age. N Engl J Med 2008; 358: 1262–70.
29. Инструкция по применению препарата Мирена, версия 12/09/2016. / Instruktsiia po primeneniiu preparata Mirena, versiia 12/09/2016. [in Russian]
30. Hassan MA, Killick SR. Is previous use of hormonal contraception associated with a detrimental effect on subsequent fecundity? Human Reprod 2004; 19 (2): 344–51.
31. Карахалис Л.Ю., Пенжоян Г.А., Могилина М.Н. Персонификация гормональной контрацепции. Гинекология. 2016; 18 (6): 67–70. / Karakhalis L.Iu., Penzhoian G.A., Mogilina M.N. Personifikatsiia gormonal'noi kontratseptsii. Ginekologiia. 2016; 18 (6): 67–70. [in Russian]
32. Кузнецова И.В. Гормональная контрацепция в коррекции нарушений менструального цикла у подростков. Репродуктивное здоровье детей и подростков. 2014; 1: 35–40. / Kuznetsova I.V. Gormonal'naia kontratseptsiia v korrektsii narushenii menstrual'nogo tsikla u podrostkov. Reproduktivnoe zdorov'e detei i podrostkov. 2014; 1: 35–40. [in Russian]

________________________________________________

1. Hillard PJ, Berek JS, Barss VA et al. Guidelines for women’s health care: A resource manual. 3rd ed. Washington, DC: American College of Obstetricians and Gynecologists, 2007.
2. Allen RH, Cwiak CA. Contraception for midlife women. Menopause 2016; 23 (1).
3. Menopauzal'naja gormonoterapija i sohranenie zdorov'ja zhenshhin v zrelom vozraste. Klinicheskie rekomendacii (protokol lechenija). Problemy reprodukcii. 2016; 6: 425–47. [in Russian]
4. Schlaff WD, Lynch AM, Hughes HD et al. Manipulation of the pill-free interval in oral contraceptive pill users: the effects on follicular suppression. Am J Obstet Gynecol 2004; 190: 943–51.
5. Sulak PJ, Scow RD, Preece C et al. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol 2000; 95: 261–6.
6. Coffee A, Kuehl TK, Willis SA, Sulak PJ. Oral contraceptives and premenstrual symptoms: comparison of a 21/7 and extended regimen. Am J Obstet Gynecol 2006; 195: 1311–9.
7. Vandever MA, Kuehl TJ, Sulak PJ et al. Evaluation of pituitary–ovarian axis suppression with three oral contraceptive regimens. Contraception 2008; 77 (3): 162–70.
8. Yonkers KA, Brown C, Pearlstein TB et al. Efficacy of a new low dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol 2005; 106: 492–501.
9. Davis AR, Kroll R, Soltes B et al. Return to menses after continuous use of a low-dose oral contraceptive. Obstet Gynecol 2006; 107: 3S.
10. Archer DF, Jensen JT, Johnson JV et al. Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results. Contraception 2006; 74 (6): 439–45.
11. Burness C.B. Extended-cycle Levonorgestrel/ethinylestradiol and low-dose ethinylestradiol (Seasonique): a review of its use as an oral contraceptive. Drugs 2015; 75 (9): 1019–26. DOI: 10.1007/s40265-015-0407-9
12. Den Tonkelaar I, Oddens BJ. Preferred frequency and characteristics of menstrual bleeding in relation to reproductive status, oral contraceptive use, and hormone replacement therapy use. Contraception 1999; 59: 357–62.
13. Andrist LC, Arias RD, Nucatola D et al. Women’s and providers’ attitudes toward menstrual suppression with extended use of oral contraceptives. Contraception 2004; 70: 359–63.
14. Glasier AF, Smith KB, van der Spuy ZM et al. Amenorrhea associated with contraception—an international study on acceptability. Contraception 2003; 67: 1–8.
15. Miller L, Hughes JP. Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: a randomized trial. Obstet Gynecol 2003; 101: 653–61.
16. Аrcher DF, Kovalevsky G, Ballagh S, Grubb GS. Effect on ovarian activity of a continuous-use regimen of oral levonorgestrel/ethinyl estradiol. Fertil Steril 2005; 84 (Suppl.): S24.
17. Gold R. Rekindling efforts to prevent unplanned pregnancy: A matter of “equity and common sense”. Guttmacher Policy Rev 2006; 9: 2–6.
18. Davis SR, Bitzer J, Giraldi A et al. Change to either a nonandrogenic or androgenic progestin-containing oral contraceptive preparation s associated with improved sexual function in women with oral contraceptive-associated sexual dysfunction. J Sex Med 2013; 10 (12): 3069–79.
19. Nappi RE, Davis SR, Parke S et al. Effects of Estradiol Valerate/Dienogest Compared with Ethinyl Estradiol/Levonorgestrel on Libido. Endocr Rev 2011; 32: 1–315.
20. Karakhalis L.Iu., Fedorovich O.K. Differentsirovannoe primenenie kombinirovannykh peroral'nykh kontratseptivov. Akusherstvo i ginekologiia. 2006; 6: 51–4. [in Russian]
21. Karakhalis L.Yu. The prolonged regime: contraceptive and non-contraceptive benefits. Consilium Medicum. 2017; 19 (6): 54–56. DOI: 10.26442/2075-1753_19.6.54-56 [in Russian]
22. Michels KA et al. Oral Contraceptive Use and Risks of Cancer in the NIH-AARP Diet and Health Study. Am J Epidemiol 2018. DOI: 10.1093/aje/kwx388
23. Shrader SP, Dickerson LM. Extended- and Continuous-Cycle Oral Contraceptives. Pharmacotherapy 2008; 28 (8): 1033–40.
24. Lidegaard O. Hormonal cointraception and venous thromboembolic risk in midlife women. Maturitas 2013; 74 (1): 1–2. DOI: 10.1016/j.maturitas.2012.09.015
25. Vinogradova Y, Coupland C, Hippisley-Cox J. Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ 2015; 350: h2135. DOI: 10.1136/bmj.h2135
26. ACOG Committee on Practice Bulletins-Gynecology. ACOG practice bulletin. No. 73: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol 2006; 107 (6): 1453–72. 
27. Department of Reproductive Health, World Health Organization. Medical Eligibility Criteria for Contraceptive Use. 4th ed. 2009. http://www.who. int/reproductivehealth/publications/family_planning/9789241563888/en/index.html 
28. Kaunitz A. Hormonal Contraception in Women of Older Reproductive Age. N Engl J Med 2008; 358: 1262–70.
29. Instruktsiia po primeneniiu preparata Mirena, versiia 12/09/2016. [in Russian]
30. Hassan MA, Killick SR. Is previous use of hormonal contraception associated with a detrimental effect on subsequent fecundity? Human Reprod 2004; 19 (2): 344–51.
31. Karakhalis L.Iu., Penzhoian G.A., Mogilina M.N. Personifikatsiia gormonal'noi kontratseptsii. Ginekologiia. 2016; 18 (6): 67–70. [in Russian]
32. Kuznetsova I.V. Gormonal'naia kontratseptsiia v korrektsii narushenii menstrual'nogo tsikla u podrostkov. Reproduktivnoe zdorov'e detei i podrostkov. 2014; 1: 35–40. [in Russian]

Л.Ю.Карахалис*

ФГБОУ ВО «Кубанский государственный медицинский университет» Минздрава России. 350063, Россия, Краснодар, ул. Седина, д. 4
*lomela@mail.ru

________________________________________________

L.Yu.Karakhalis* 

Kuban State Medical University of the Ministry of Health of the Russian Federation. 350063, Russian Federation, Krasnodar, ul. Sedina, d. 4
*lomela@mail.ru